CPhI Think Tank 2022: New Drug Development & Collaboration Summit Kicks Off in Suzhou This August!
In recent years, China’s pharmaceutical innovation has gradually shifted from imitation to independent innovation, achieving a qualitative leap in both the quantity and quality of new drug development. This progress has strongly propelled China’s transformation from a major pharmaceutical country into a global pharmaceutical powerhouse. Against the backdrop of rapid advancements in pharmaceutical innovation,CPhI “Think Tank” — 2022 Summit on New Drug Development and CollaborationSetting sail once again, this year’s summit will be themed “Creating New Vitality • Sharing New Wisdom.” It will bring together industry leaders and experts to accelerate the development and refinement of the innovative drug ecosystem, provide strategic insights into pharmaceutical innovation in China for the new era, and contribute Chinese wisdom to global open cooperation and coordinated development.
Time:August 18–19, 2022
Location:Suzhou Dantai Lake Hotel
Host:China Chamber of Commerce for Import and Export of Medicines and Health Products
Co-organizers:Suzhou Wuzhong District Pharmaceutical Industry Chamber of Commerce
Organizer:Shanghai Informa Markets Exhibition Co., Ltd.
Ticket Purchase Methods:
Click the text (link) below to open it in your browser and purchase tickets.
CPhI “Think Tank” Ticket Purchase (http://newdrug.cphi-china.cn/wx/zhuce?partner_id=96）
Topic Focus
Global Pharmaceutical Innovation: Small-Molecule Innovative Drugs, Biologic Innovative Drugs, Novel Vaccines, and mRNA;
Keynote Address
Pharmaceutical companies, R&D institutions related to chemical drugs/biologics/vaccines, pharmaceutical instrument and equipment manufacturers, testing agencies, upstream and downstream industry-related enterprises, as well as universities and research institutes;
Diverse Sharing
Classes are organized by topic, with lectures as the primary format and interactive Q&A sessions as a supplementary component;
Precision Networking
80+ Industry Leaders Gather in the Classroom; A Feast of Insights from 1,000+ Industry Experts;
Brand Building
Build diversified and customized brands.
Sneak Peek at Trending Topics
Keynote Address
● New Drug Development and Industrial Growth under the 14th Five-Year Plan
● Difficulties and Challenges in the Research and Development of Innovative Drugs
● Clinical Value-Driven Drug Innovation
● Development of Intracellular Internalization-Based Targeted GPCR Peptide-Drug Conjugation Methods and Drug R&D
● Development Strategies for Next-Generation Cell Therapies
● Innovative Technology Services Empowering New Drug Development
Fireside Chat
● China’s Opportunities in Source Innovation
● Building an Innovation Ecosystem to Activate the Sources of Innovation
● Illuminating New Wisdom: The New Strategic Landscape for External Collaborations Among Chinese Innovative Pharmaceutical Companies
● In China for Global: Global Regulatory Submission and Clinical Development Strategies for Innovative Drugs
● Integrating into Globalization: The Advanced “Secret” to License-Out Deals for China’s Innovative Drugs
Keynote Address
● Discovery and Druggability Evaluation of Small-Molecule STING Agonists
● Research and Development of Small-Molecule ERK Inhibitors Targeting a Highly Promising Kinase
● Development of Small-Molecule Allosteric Inhibitors and Undruggable Targets
● Frontier Advances in the R&D of Small-Molecule Targeted Therapeutics
Roundtable Discussion
● What is the biggest challenge facing first-in-class drugs with novel targets and mechanisms?
● From Theory to Practice: How New Technologies Are Unlocking New Paradigms and Applications in Small-Molecule Drug Discovery
● Accelerating Innovation: How to Address New Challenges in the Development of First-in-Class (FIC) Drugs?
● New Strategies for Accelerating Drug Development through Translational Medicine in the Era of Precision Medicine?
Keynote Address
● R&D Strategy in an Innovative Environment
● Antibody Development Strategies in the NK Cell Field
● Development of Novel Bispecific Antibody Immunotherapies
● ADC Drugs: Precision-Guided Therapy and an Increasingly Mature Novel Drug Platform
● Platform technology innovation and new drug development in ADCs, benchmarked against DS-8201
● FDA’s Focus and Considerations in Vaccine Review
● mRNA Therapeutics: From Delivery to Clinical Application
● mRNA Cancer Vaccines
● Circular RNA Therapeutics
● WES and RNA-Seq Facilitate mRNA Drug Development
● Considerations for the mRNA Drug R&D Industry Chain
Roundtable Discussion
● With crowded pipelines and intensifying competition, where is original innovation in biologics headed?
● How ADC Drug Developers Are Iterating on Innovation to Compete for the Next Trillion-Yuan Blue Ocean
● Future Research Strategies and Development Trends for Novel Vaccines: Where Do the Opportunities for Leapfrogging Lie?
● How to overcome the difficulties and challenges in mRNA vaccine delivery, manufacturing processes, and production?
(Note: The agenda is subject to continuous updates; please refer to the actual on-site schedule.)
Academician Zhang Dan, Chief Scientist at Xingwan Biology
Xia Mingde, CEO of InnoLake Pharma
Zhang Lianshan, Vice General Manager and President of Global R&D at Hengrui Medicine
Huang Jingfeng, Founder & CEO of Shengyuan Pharmaceutical
Zhang Nong, Executive Vice President of Zaiji Pharma
Yang Dajun, CEO of Ascentage Pharma
Lu Lulu, CEO of Heyuan Bio
Liu Xiaoling, Partner at ETP Fund
Dai Han, Chief Innovation Officer and Head of Investment at WuXi Biologics
Yang Yong, Dean of the School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
TBD, Expert from WuZhong Industrial Park
Li Ning, Assistant to the President of the Cancer Hospital, Chinese Academy of Medical Sciences; Dean of Hebei Pharmaceutical University
Tian Changlin, Professor and Doctoral Supervisor at the University of Science and Technology of China; National Distinguished Young Scholar
Zhang Peiyu, Chief Scientific Officer at XtalPi
Bian Feng, Executive Director, BMS; Head of Integrated Science Team, China, Global Drug R&D
Liu Jingwen, CEO of Xiwei'ai Pharmaceuticals
Yang Yi, Chief Scientist at Biocytogen
Cao Fei, Co-founder & Chief Operating Officer of Adagene
Yan Shuizhong, Chief Operating Officer of Global R&D at Zai Lab
Fu Meng, CEO of Readmed Pharma
Wei Xiaoxiong, Founder of Handu Pharma
Wang Junyuan, CEO of Baoyuan Medicine
Xiao Kai, VP of Corporate & BD at Taili Bio
Wang Kuifeng, CEO of Qinhao Pharma
Zhou Sixiang, Vice President of Sinogen Pharmaceutical
Xu Yinglin, Xunuo Pharmaceutical
Zhu Wei, Head of the Department of Medicinal Chemistry, Roche Shanghai Innovation Center
Wu Yusheng, Chairman and President of Tongyuan Kang Pharmaceutical
Li Zhiyu, China Pharmaceutical University
Ren Delin, Executive Director and President of WuXi Biologics
Wang Yonghui, Founder & Chairman of Huiqi Bio
Chen Xiaoxin, Founder of Zhongsheng Ruichuang
Chen Chunlin, CEO of Medicilon
Shan Bo, CSO of Antengene
Gu Xiao, Director of Drug Registration Management at Nanjing Pharmaron Technology Co., Ltd.
Zhang Yantao, CEO of Taili Bio
Long Wei, Executive Vice President of Preclinical R&D at Jacobio Pharmaceuticals
Wang Kuifeng, CEO of QinHao Pharma
Lin Dongxu, Head of R&D at MedPace
Yu Qiang, CEO of Shengshi Taike
Hu Yonghan, CTO of Xinnowei
Peng Peng, Vice President of Advenchen Laboratories
Huang Haomin, Vice President of R&D at 3SBio Inc.
Dai Chaohui, CEO and Chief Operating Officer of Huaiyue Bio
Yuan Qing’an, CSO of iCoast (Beijing)
Wang Yuchong, Founder & CEO of Chenan Biologics
Yang Yi, Chief Scientist at Biocytogen
Zhang Fuyao, Chairman of Biling Biotech
Cai Jiaqiang, CSO of Yilian Biologics
Huang Hao, Analyst at Haitong Securities
Huang Yunsheng, CTO of Hangzhou Aikeruisi Biopharmaceutical Co., Ltd.
Qin Gang, CEO of Qide Medicine
Du Heng, Senior Program Officer, Health Innovation and Collaboration Department, Bill & Melinda Gates Foundation China Representative Office
Gao Guang, Senior Technical Officer, PATH
Pan Huirong, Deputy General Manager of Wantai Biotechnology
Shen Haifa, CTO of Stemirna
Xia Xiaojun, Researcher and Doctoral Supervisor at Sun Yat-sen University Cancer Center/State Key Laboratory of Oncology in South China
TBD, Schott
Liu Xin, Principal Investigator and Research Group Leader at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
Xiong Lei, Founder of 3D Medicines Diagnostics (Invitation Pending)
Zhou Qihao, VP of Yeasen Biotechnology (Invitation Pending)
More industry leaders are joining—stay tuned…
(Note: Guests are listed in no particular order.)
Pharmaceutical Companies | Biotechnology Companies | Research Institutes | Pharmaceutical R&D Institutions | CRO/CDMO/CMO | Government Agencies | Instruments & Equipment | Reagents & Consumables | Industry Associations/Alliances | Consulting/Law Firms/Investment Firms | Industrial Parks | Others
Click the text (link) below to open in your browser and purchase tickets.
CPhI “Think Tank” Ticket Purchase (http://newdrug.cphi-china.cn/wx/zhuce?partner_id=96）
Register early to enter the prize draw!
Ms. Mao
Tel: 021-33392250
Email: chris.mao@imsinoexpo.com
Ms. Zheng
Tel: 010-58036337
Email: zhengyumeng@cccmhpie.org.cn
